首页> 外文OA文献 >Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

【2h】

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

机译：伴随服用异环磷酰胺减少了舒尼替尼的暴露：晚期固体恶性肿瘤患者联合舒尼替尼和异环磷酰胺的I期和药代动力学研究结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Hamberg, A.P. (Paul); Steeghs, N. (Neeltje); Loos, W.J. (Walter); Biessen, D. van de; Hollander, M. den; Tascilar, M. (Metin); Verweij, J. (Jaap); Gelderblom, A.J. (Hans); Sleijfer, S. (Stefan);
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies [J] . P Hamberg, N Steeghs, W J Loos, British Journal of Cancer . 2010,第12期

机译：异环磷酰胺同时给药可减少舒尼替尼的暴露：晚期固体恶性肿瘤患者联合舒尼替尼和异环磷酰胺的I期和药代动力学研究结果
2. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. [J] . L Q M Chow, N Blais, D J Jonker, Cancer chemotherapy and pharmacology. . 2012,第3期

机译：舒尼替尼联合培美曲塞在晚期实体恶性肿瘤患者中的I期剂量递增和药代动力学研究，并扩大了非小细胞肺癌的队列。
3. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer [J] . L. Q. M. Chow, N. Blais, D. J. Jonker, Cancer Chemotherapy and Pharmacology . 2012,第3期

机译：舒尼替尼联合培美曲塞治疗晚期实体恶性肿瘤且非小细胞肺癌队列扩大的I期剂量递增和药代动力学研究
4. Solid-phase exaction-liquid chromatographic method for the determination and pharmacokinetic studies of albiflorin and paeoniflorin in rat serum after oral administration of Si-Wu decoction [C] . 北京大学中医药现代研究中心2004年年会论文集 . 2005

机译：四物汤口服后固相分离-液相色谱法测定大鼠血清中白花素和pa药苷的含量及药动学
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies [O] . P Hamberg, N Steeghs, W J Loos, 2010

机译：异烟酰胺同时给药可降低舒尼替尼的暴露：晚期固体恶性肿瘤患者联合舒尼替尼和异环磷酰胺的I期和药代动力学研究结果
7. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies [O] . Hamberg, P, Steeghs, N, Loos, W J, 2010

机译：伴随服用异环磷酰胺减少了舒尼替尼的暴露：晚期固体恶性肿瘤患者联合舒尼替尼和异环磷酰胺的I期和药代动力学研究结果

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

著录项

相似文献

相关主题

期刊订阅